Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

176 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature.
Kuendgen A, Müller-Thomas C, Lauseker M, Haferlach T, Urbaniak P, Schroeder T, Brings C, Wulfert M, Meggendorfer M, Hildebrandt B, Betz B, Royer-Pokora B, Gattermann N, Haas R, Germing U, Götze KS. Kuendgen A, et al. Among authors: meggendorfer m. Oncotarget. 2018 Jun 12;9(45):27882-27894. doi: 10.18632/oncotarget.25328. eCollection 2018 Jun 12. Oncotarget. 2018. PMID: 29963245 Free PMC article. Review.
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML).
Meggendorfer M, Roller A, Haferlach T, Eder C, Dicker F, Grossmann V, Kohlmann A, Alpermann T, Yoshida K, Ogawa S, Koeffler HP, Kern W, Haferlach C, Schnittger S. Meggendorfer M, et al. Blood. 2012 Oct 11;120(15):3080-8. doi: 10.1182/blood-2012-01-404863. Epub 2012 Aug 23. Blood. 2012. PMID: 22919025 Free PMC article.
Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact.
Bacher U, Haferlach T, Schnittger S, Zenger M, Meggendorfer M, Jeromin S, Roller A, Grossmann V, Krauth MT, Alpermann T, Kern W, Haferlach C. Bacher U, et al. Among authors: meggendorfer m. Br J Haematol. 2014 Mar;164(6):822-33. doi: 10.1111/bjh.12710. Epub 2013 Dec 26. Br J Haematol. 2014. PMID: 24372512 Free article.
BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia.
Weber S, Alpermann T, Dicker F, Jeromin S, Nadarajah N, Eder C, Fasan A, Kohlmann A, Meggendorfer M, Haferlach C, Kern W, Haferlach T, Schnittger S. Weber S, et al. Among authors: meggendorfer m. Blood Cancer J. 2014 Jan 10;4(1):e173. doi: 10.1038/bcj.2013.71. Blood Cancer J. 2014. PMID: 24413067 Free PMC article.
Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations.
Jeromin S, Haferlach T, Weissmann S, Meggendorfer M, Eder C, Nadarajah N, Alpermann T, Kohlmann A, Kern W, Haferlach C, Schnittger S. Jeromin S, et al. Among authors: meggendorfer m. Haematologica. 2015 Apr;100(4):e125-7. doi: 10.3324/haematol.2014.119032. Epub 2014 Dec 19. Haematologica. 2015. PMID: 25527566 Free PMC article. No abstract available.
Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q.
Heuser M, Meggendorfer M, Cruz MM, Fabisch J, Klesse S, Köhler L, Göhring G, Ganster C, Shirneshan K, Gutermuth A, Cerny-Reiterer S, Krönke J, Panagiota V, Haferlach C, Koenecke C, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Ehrlich S, Stamer K, Döhner K, Valent P, Schlegelberger B, Kroeger N, Ganser A, Haase D, Haferlach T, Thol F. Heuser M, et al. Among authors: meggendorfer m. Leukemia. 2015 Sep;29(9):1942-5. doi: 10.1038/leu.2015.49. Epub 2015 Feb 24. Leukemia. 2015. PMID: 25792355 No abstract available.
176 results